Merck, CRT in deal for PRMT5 inhibitors
Merck & Co. Inc. (NYSE:MRK) partnered with Cancer Research Technology Ltd. to develop inhibitors of protein arginine methyltransferase 5, which the companies said have potential to treat cancer and non-cancer blood disorders.
The inhibitors were developed by Australian cooperative research center Cancer Therapeutics CRC Pty Ltd. (CTx) (Melbourne, Australia), with...
Read the full 245 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Extra
Article Purchase
$35 USD
